



ADAP Advocacy Association
PO Box 846
Nags Head, NC 27959

adapadvocacy.org

Board of Directors:

Co-Chair

Philip A. Haddad, M.D.
Shreveport, LA

Co-Chair

Jen Laws
Slidell, LA

Secretary

Guy Anthony
Brooklyn, NY

Treasurer

Wanda Brendle-Moss
Winston-Salem, NC

Elmer Cerano
Lansing, MI

Eric Flowers
Oakland, CA

Lyne Fortin
Montreal, Canada

Hilary M. Hansen
Washington, DC

Lisa Johnson-Lett
Birmingham, AL

Theresa Nowlin
Dorchester, MA

Glen Pietrandoni, R.Ph.
Chicago, IL

Jennifer Vaughan
Watsonville, CA

CEO

Brandon M. Macsata
Washington, D.C.

Directors Emeritus:

Michelle Anderson
William Arnold – *in memoriam*
John D. Kemp, Esq.
Gary Rose – *in memoriam*
Joyce Turner Keller
Rani Whitfield, MD

ADAP Advocacy Association Launches Ryan White Grantee 340B Project

Appoints Ryan White Grantee 340B Patient Advisory Committee

For Immediate Release:
November 16, 2022

Media Contact:
info@adapadvocacy.org

WASHINGTON, D.C. – The ADAP Advocacy Association today launched its Ryan White Grantees 340B Project, which is designed to provide education, resources, and tools for patients seeking to participate in the national conversation about reforming the 340B Drug Discount Program. A focal point of the project will be a Ryan White Grantee 340B Patient Advisory Committee.

Brandon M. Macsata, CEO of the ADAP Advocacy Association, summarized: “Our organization has a solid track-record leveraging its patients advisory committees, which have included ones focused on drug formularies, as well as long-acting agent injectable therapies. Our new Ryan White Grantee 340B Patient Advisory Committee will put patients first, not providers, and it will evaluate reform proposals through the lenses: *what would best serve patients.*”

AIDS Drug Assistance Programs are categorically eligible for the 340B Drug Pricing Program,¹ and rebates received through their participation represents a significant source of revenue. The Ryan White HIV/AIDS Program can expand access to care and treatment for patients, in part, because 340B rebate dollars exist, and as such program integrity is of paramount importance.

Since its inception, the program has grown dramatically, and with it so have the challenges, opportunities, and the questions of whether what was created 26 years ago should be re-cast? While advocates argue that the status quo is good enough, others are asking questions that get to the heart of the future of the program. Is this program benefiting nonprofit healthcare providers or patients who do not have prescription drug coverage? Are nonprofit hospitals and other 340B providers treated equally or are there different levels of transparency rules? Are all 340B providers required to reinvest their 340B revenue in patient care and staffing, or is the program so opaque that the rules are disproportionately benefiting one certain kind of 340B providers?

To learn more about the ADAP Advocacy Association, AIDS Drug Assistance Programs, or 340B, please email info@adapadvocacy.org.

####

About the ADAP Advocacy Association: The ADAP Advocacy Association mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improves access to care for persons living with HIV/AIDS. **aaa+**[®] works with advocates, community, health care, government, patients, pharmaceutical companies and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.

¹ National Alliance of State & Territorial AIDS Directors (June 2018). Best Practices for Shared ADAP and 340B Drug Pricing Program Clients. Retrieved online at <https://nastad.org/sites/default/files/2021-12/PDF-ADAP-340B-Best-Practices.pdf>